"Among the patients not receiving memantine, the mean SIB change at the average of week 13 and week 15 time points from baseline was significantly greater in the 20µg bryostatin arm as compared to placebo patients (difference (95% CI)=6.1 (1.5, 10.7) points; p=0.012)."
Or to put it more simply:
Among the patients not receiving memantine, there was a 98.8% chance that the mean SIB change from baseline at the average of week 13 and week 15 was significantly greater in the 20µg bryostatin arm as compared to placebo patients.